Highlights

• Sales Revenue rose 2% in constant currency to $2.3bn; underlying NPAT was $322m

• Cochlear implant units increased 5% to 56,692, with average 3% pricing uplift from Nucleus Nexa

• Nucleus Nexa represented more than 95% of implant sales in developed markets by June 2026

• Free Cash Flow increased $141m to $264m; R&D spend rose 15% for next-generation device pipeline

Cochlear Limited (ASX:COH) is one of Australia's most iconic global medical technology companies and the world's leading manufacturer of cochlear implant systems. The company develops, manufactures and markets implantable hearing solutions for people with moderate to profound hearing loss, operating across more than 100 countries through its branded Nucleus cochlear implant and Baha bone-anchored hearing systems. With a history spanning more than 40 years, Cochlear has built an extraordinary installed base of recipients, generating significant Recurring Revenue from sound processor upgrades and accessories. The company is widely regarded as a high-quality compounder with exposure to a growing global addressable market.

Latest Developments

Cochlear's FY26 result was mixed: sales revenue rose 2% in constant currency to $2.3bn, but underlying NPAT was $322m, reflecting Margin pressure, flat implant revenue and restructuring/transitional costs. Cochlear implant units nevertheless increased 5% to 56,692, while free cash flow increased by $141m to $264m. A major strategic development was the launch of the Nucleus Nexa system; by June, Nexa represented more than 95% of implant sales across developed markets and supported an average 3% price increase. R&D Investment increased 15%, with the company continuing work on technologies including a drug-eluting electrode and totally implantable cochlear implant.

Industry Context

The global hearing loss market is one of the most compelling demographic stories in medical technology. The World Health Organization estimates that over 1.5 billion people globally experience some degree of hearing loss, with approximately 430 million requiring rehabilitation. Despite this large population, cochlear implant penetration rates remain low — typically under 10% of eligible candidates globally receive implants — creating a long runway of addressable market growth. The sector is characterised by high barriers to entry, strong physician relationships and a recurring revenue model through processor upgrades, making it attractive to long-term investors.

Key Risks

• Currency headwinds remain significant given Cochlear's revenue is predominantly in USD and EUR but costs are partly AUD

• Restructuring and transitional costs associated with the Nucleus Nexa launch may persist into FY27

• Competitive pressure from MED-EL and Advanced Bionics (Sonova) in key developed markets

• R&D pipeline risk — the totally implantable cochlear implant and drug-eluting electrode are long-dated development programs

• Healthcare reimbursement policy changes in key markets (US, Europe) could impact implant approval and funding rates

Key Catalysts to Watch

• Nucleus Nexa system driving continued pricing uplift and Market Share gains as global rollout completes

• R&D milestones on the totally implantable cochlear implant — a potential step-change product

• Developing market penetration improvement as reimbursement systems mature in China, India and Southeast Asia

• Free cash flow continuing to grow, enabling increased Capital returns or accelerated R&D investment

• Regulatory approvals for new indications (e.g., single-sided deafness) expanding the eligible patient population

Conclusion

Cochlear (ASX:COH) remains one of the highest-quality businesses on the ASX, combining market leadership, high barriers to entry, a growing global addressable market and a strong R&D pipeline. The FY26 result was not exceptional, with margin pressure and restructuring costs weighing on NPAT, but the unit Volume growth, Nucleus Nexa launch success and free cash flow improvement all confirm the business's underlying health. Long-term investors in COH are backing the global hearing loss adoption curve, and FY27 should see the Nexa-led pricing uplift flowing through more cleanly.